Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
Nuvelo completes enrollment in Phase III trial of alfimeprase in acute arterial occlusion
October 5th, 2006
Nuvelo, Inc. (NUVO) has completed patient enrollment in the first Phase III clinical trial of alfimeprase for the treatment of acute peripheral arterial occlusion (PAO), or "leg attack." The Phase III trial, known as NAPA-2 (Novel Arterial Perfusion with Alfimeprase-2), is the first of two multinational trials in the Phase III alfimeprase program for acute PAO. This randomized, double-blind study compared the efficacy and safety of 0.3 mg/kg of alfimeprase versus placebo in approximately 300 patients in over 100 centers worldwide. The study's primary endpoint is avoidance of open vascular surgery within 30 days of treatment. Open vascular surgery...
Source: Blood Weekly (2006-10-05)
|
